PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on PepGen Inc. yesterday and set a price target of $3.00. The company’s sh...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PEPG	$5.66	-1.39%	314.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PEPG	$5.66	-1.4%	314.35K
3
4
5
6

PEPG

PEPG

Latest News for PEPG

Get PepGen Inc. Data in Excel

Get PepGen Inc. Data in Excel